Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
Dynamic Observational Strategy for Stage IB-IIIA Non-Small Cell Lung Cancer Patients After Complete Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yi-Long Wu, M.D
- Phone Number: 020-83827812
- Email: syylwu@live.cn
Study Contact Backup
- Name: Xue-Ning Yang, Ph.D
- Phone Number: 020-83827812
- Email: yangxuening@gdph.org.cn
Study Locations
-
-
Guangdong
-
Foshan, Guangdong, China, 528000
- Recruiting
- The First People's Hospital of Foshan
-
Contact:
- Weiquan Gu
- Phone Number: 086-0757-83163155
- Email: gwquan@fsyyy.com
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
-
Contact:
- Wen-Zhao Zhong, MD
-
Contact:
- Yi-Long Wu, MD
- Phone Number: 51221 +86 20 83827812
- Email: syylwu@live.cn
-
Principal Investigator:
- Yi-Long Wu, MD
-
Sub-Investigator:
- Wen-Zhao Zhong, MD
-
Shantou, Guangdong, China, 515041
- Recruiting
- the First Affiliated Hospital of Shantou University Medical College
-
Contact:
- Zefeng Xie
- Phone Number: 086-0754-88258290
- Email: zefengxie@sina.com
-
Shantou, Guangdong, China, 515031
- Recruiting
- Shantou Centeral Hospital
-
Contact:
- Yanlong Yang
- Phone Number: 086-0754-88550450
- Email: styylong@163.com
-
Zhongshan, Guangdong, China, 528445
- Recruiting
- Zhongshan City People's Hospital
-
Contact:
- Yi Liang, MD
- Phone Number: 086-0760-88823566
- Email: yiliang2020@qq.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Stage IB-IIIA non-small cell cancer patients who after complete resection.
- ≥18 years.
- Two-round MRD tests confirm landmark undetectable MRD.
- Expected survival ≥12 weeks.
- Expected survival ≥12 weeks.
- ECOG PS 1-2.
- Willing to accept MRD monitoring every 3 months for a total of 2 years after operation.
Exclusion Criteria:
- Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy.
- Patients with a history of other malignancies in the past 5 years.
- Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Undetectable MRD
Stage IB-IIIA NSCLC patients who after complete resection.
And patients who maintain MRD negativity in two-round MRD landmark test (first in 3-7 days after surgery, second in 1 months ±7 days after surgery) will be enrolled.
And patients will be under close dynamic monitoring at least two years.
|
OncoMRD Lung
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Two-years disease free survival rates for patients with longitudinal undetectable MRD
Time Frame: 2 year
|
The 2-year DFS rate of patients who maintain 2-years undetectable MRD.
|
2 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Two-years disease free survival rates for patients with six months longitudinal undetectable MRD
Time Frame: 2 year
|
The 2-year DFS rate of patients who maintain 6-months undetectable MRD.
|
2 year
|
|
Two-years disease free survival rates for patients with 12-months longitudinal undetectable MRD
Time Frame: 2 year
|
The 2-year DFS rate of patients who maintain 12-months undetectable MRD.
|
2 year
|
|
Two-years disease free survival rates for patients with 18-months longitudinal undetectable MRD
Time Frame: 2 year
|
The 2-year DFS rate of patients who maintain 18-months undetectable MRD.
|
2 year
|
|
Two-years event-free survival rates for enrolled patients in two years
Time Frame: 2 year
|
The events are defined as disease recurrence or detectable MRD.
|
2 year
|
|
Two-years disease free survival rates for patients who tested positive for MRD and failed screening during the two-round MRD tests.
Time Frame: 2 year
|
The 2-year DFS rate of patients who tested positive for MRD and failed screening during the two-round MRD tests.
|
2 year
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Zhang JT, Liu SY, Gao W, Liu SM, Yan HH, Ji L, Chen Y, Gong Y, Lu HL, Lin JT, Yin K, Jiang BY, Nie Q, Liao RQ, Dong S, Guan Y, Dai P, Zhang XC, Yang JJ, Tu HY, Xia X, Yi X, Zhou Q, Zhong WZ, Yang XN, Wu YL. Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer. Cancer Discov. 2022 Jul 6;12(7):1690-1701. doi: 10.1158/2159-8290.CD-21-1486.
- Huang Z, He J, Li Y, Xu Z, Peng H, Gao X, Zhou H, Guo J, Yang N. Non-invasive radiogenomic mapping of the SMARCAL1-driven ferroptotic niche is associated with longitudinal MRD-negative surveillance in early-stage NSCLC. Front Immunol. 2026 May 25;17:1835413. doi: 10.3389/fimmu.2026.1835413. eCollection 2026.
- Zhang JT, Dong S, Gu WQ, Zhao N, Liang Y, Tang WF, Liu SY, Wang F, Wang GS, Peng B, Wu N, Yan S, Geng GJ, Xie ZF, Yang YL, Zhang JH, Zhang T, Yang N, Jiao WJ, Xiong YY, Cai M, Li F, Chen RR, Yan HH, Maggie Liu SY, Yi X, Zhong WZ, Yang XN, Wu YL. Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201). Clin Lung Cancer. 2024 Jan;25(1):e1-e4. doi: 10.1016/j.cllc.2023.09.008. Epub 2023 Oct 6.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTONG 2201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.